| Donor age and type in allogeneic haematopoietic stem cell transplantation: Strong effect in MDS, limited in AML |
|
British Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
| Drug development in higher-risk myelodysplastic syndromes |
|
Blood Cancer Journal |
Myelodysplastic Syndromes (MDS) |
| Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS) |
|
Cochrane Database of Systematic Reviews |
Myelodysplastic Syndromes (MDS) |
| Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes |
|
Journal of Internal Medicine |
Myelodysplastic Syndromes (MDS) |
| Eat and be healthy: nutritional status in myelodysplastic syndromes |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series |
|
Annals of Hematology |
Aplastic Anemia |
| Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry |
|
Am J Hematol |
Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Efficacy and Safety of Inhibitors of the Proximal Pathway of the Complement System in Paroxysmal Nocturnal Hemoglobinuria: A Meta-analysis of Randomized Controlled Trials |
|
American Journal of Therapeutics |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial |
|
Lancet |
Myelodysplastic Syndromes (MDS) |
| Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial |
|
Lancet |
Myelodysplastic Syndromes (MDS) |
